Jacobs Levy Equity Management
IGMS

Jacobs Levy Equity Management’s IGM Biosciences IGMS Stock Holding History

Jacobs Levy Equity Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-78,580
Closed -$758K – 1005
2024
Q1 		$758K Buy
+78,580
New +$911K ﹤0.01% 764
2023
Q4 		– Sell
-56,237
Closed -$470K – 1018
2023
Q3 		$470K Sell
56,237
-81,338
-59% -$690K ﹤0.01% 811
2023
Q2 		$1.27M Buy
+137,575
New +$1.54M 0.01% 653

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's IGMS Position: Q2 2024 in Review

Jacobs Levy Equity Management sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 78,580 shares — an estimated $758K sold.

Jacobs Levy Equity Management first reported a position in IGMS in Q2 2023 and held it in 3 quarters. The position peaked at $1.27M in Q2 2023. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

  • Jacobs Levy Equity Management reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 78,580 IGM Biosciences shares in Q2 2024, an estimated $758K.
  • Jacobs Levy Equity Management first reported a position in IGM Biosciences in Q2 2023 and held it in 3 quarters.
  • Jacobs Levy Equity Management's IGM Biosciences position peaked at $1.27M in Q2 2023.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2024, filed 14 Aug 2024.